OSI Pharmaceuticals Appoints Barbara A. Wood, Esq., General Counsel and Linda E. Amper, Ph.D., Vice President, Human Resources and Administration

Apr 25, 2001, 01:00 ET from OSI Pharmaceuticals, Inc.

    UNIONDALE, N.Y., April 25 /PRNewswire/ -- OSI Pharmaceuticals, Inc.
 (Nasdaq: OSIP) today announced the appointments of Barbara A. Wood, Esq., as
 General Counsel and Linda E. Amper, Ph.D., as Vice President, Human Resources
 and Administration.  Ms. Wood and Dr. Amper both report to Colin Goddard,
 Ph.D., Chairman and Chief Executive Officer and serve as members of OSI's
 Corporate Management Committee.
     "As General Counsel, Barbara brings to OSI tremendous experience and legal
 knowledge in the biotechnology area," stated Dr. Goddard.  "With over 13 years
 of experience in private practice, including extensive work with OSI as our
 external legal counsel, she will contribute valuable day-to-day insight to our
 business strategy."
     "We are also pleased to welcome Linda Amper to OSI," stated Dr. Goddard.
 "As a former Executive Director of the Long Island region of the New York
 Blood Center, Linda combines proven strength as an administrative leader in
 the healthcare industry with her extensive experience in human resources.  She
 will be a fine addition to our senior management team."
     As in-house general counsel, Ms. Wood, 39, will be responsible for a wide
 range of legal matters, including corporate development and securities
 matters, both domestically and internationally.  Before she joined OSI,
 Ms. Wood was as a partner in the Corporate Department of the New York office
 of Squadron Ellenoff Plesent & Sheinfeld LLP where she began her legal career
 in 1987.  Her areas of expertise encompass mergers and acquisitions, complex
 licensing transactions, private and public securities offerings, venture
 capital investments, and the formation of joint ventures and partnerships.
 Ms. Wood holds a Bachelor of Arts degree from Connecticut College and a J.D.
 from Columbia Law School in New York.
     Dr. Amper, 44, will be responsible for human resources and administration
 on a company-wide basis and will oversee facility operations at OSI's various
 locations.  Prior to joining OSI, Dr. Amper was with the New York Blood Center
 since 1978.  Most recently she served as the Executive Director and Vice
 President of Long Island Blood Services, a division of the New York Blood
 Center, and immediately prior to that position, as Vice President, Human
 Resources for the New York Blood Center.  Dr. Amper holds a Ph.D. in
 Philosophy, Health Administration from Columbia Southern, a Master of Public
 Administration with a specialization in Health Care from C.W. Post College,
 and a Bachelor of Science, Medical Biology also from C.W. Post College.
     OSI Pharmaceuticals is a leading biopharmaceutical company with a
 substantial portfolio of product opportunities for commercialization with the
 pharmaceutical industry.  OSI's research programs are focused in the areas of
 cancer therapeutics, respiratory diseases, diabetes, and cosmeceuticals.  OSI
 utilizes a comprehensive drug discovery and development capability to
 facilitate the rapid and cost-effective discovery and development of novel,
 small molecule compounds against more than 40 gene targets.
     Additional information on OSI Pharmaceuticals is available on the World
 Wide Web at http://www.osip.com.
 
     This news release contains forward-looking statements.  These statements
 are subject to known and unknown risks and uncertainties that may cause actual
 future experience and results to differ materially from the statements made.
 Factors that might cause such a difference include, among others,
 uncertainties related to the identification of lead compounds, the successful
 pre-clinical development thereof, the completion of clinical trials, the FDA
 review process and other governmental regulation, pharmaceutical
 collaborators' ability to successfully develop and commercialize drug
 candidates, competition from other pharmaceutical companies, product pricing
 and third part reimbursement, and other factors described in OSI
 Pharmaceuticals' filings with the Securities and Exchange Commission.
 
 

SOURCE OSI Pharmaceuticals, Inc.
    UNIONDALE, N.Y., April 25 /PRNewswire/ -- OSI Pharmaceuticals, Inc.
 (Nasdaq: OSIP) today announced the appointments of Barbara A. Wood, Esq., as
 General Counsel and Linda E. Amper, Ph.D., as Vice President, Human Resources
 and Administration.  Ms. Wood and Dr. Amper both report to Colin Goddard,
 Ph.D., Chairman and Chief Executive Officer and serve as members of OSI's
 Corporate Management Committee.
     "As General Counsel, Barbara brings to OSI tremendous experience and legal
 knowledge in the biotechnology area," stated Dr. Goddard.  "With over 13 years
 of experience in private practice, including extensive work with OSI as our
 external legal counsel, she will contribute valuable day-to-day insight to our
 business strategy."
     "We are also pleased to welcome Linda Amper to OSI," stated Dr. Goddard.
 "As a former Executive Director of the Long Island region of the New York
 Blood Center, Linda combines proven strength as an administrative leader in
 the healthcare industry with her extensive experience in human resources.  She
 will be a fine addition to our senior management team."
     As in-house general counsel, Ms. Wood, 39, will be responsible for a wide
 range of legal matters, including corporate development and securities
 matters, both domestically and internationally.  Before she joined OSI,
 Ms. Wood was as a partner in the Corporate Department of the New York office
 of Squadron Ellenoff Plesent & Sheinfeld LLP where she began her legal career
 in 1987.  Her areas of expertise encompass mergers and acquisitions, complex
 licensing transactions, private and public securities offerings, venture
 capital investments, and the formation of joint ventures and partnerships.
 Ms. Wood holds a Bachelor of Arts degree from Connecticut College and a J.D.
 from Columbia Law School in New York.
     Dr. Amper, 44, will be responsible for human resources and administration
 on a company-wide basis and will oversee facility operations at OSI's various
 locations.  Prior to joining OSI, Dr. Amper was with the New York Blood Center
 since 1978.  Most recently she served as the Executive Director and Vice
 President of Long Island Blood Services, a division of the New York Blood
 Center, and immediately prior to that position, as Vice President, Human
 Resources for the New York Blood Center.  Dr. Amper holds a Ph.D. in
 Philosophy, Health Administration from Columbia Southern, a Master of Public
 Administration with a specialization in Health Care from C.W. Post College,
 and a Bachelor of Science, Medical Biology also from C.W. Post College.
     OSI Pharmaceuticals is a leading biopharmaceutical company with a
 substantial portfolio of product opportunities for commercialization with the
 pharmaceutical industry.  OSI's research programs are focused in the areas of
 cancer therapeutics, respiratory diseases, diabetes, and cosmeceuticals.  OSI
 utilizes a comprehensive drug discovery and development capability to
 facilitate the rapid and cost-effective discovery and development of novel,
 small molecule compounds against more than 40 gene targets.
     Additional information on OSI Pharmaceuticals is available on the World
 Wide Web at http://www.osip.com.
 
     This news release contains forward-looking statements.  These statements
 are subject to known and unknown risks and uncertainties that may cause actual
 future experience and results to differ materially from the statements made.
 Factors that might cause such a difference include, among others,
 uncertainties related to the identification of lead compounds, the successful
 pre-clinical development thereof, the completion of clinical trials, the FDA
 review process and other governmental regulation, pharmaceutical
 collaborators' ability to successfully develop and commercialize drug
 candidates, competition from other pharmaceutical companies, product pricing
 and third part reimbursement, and other factors described in OSI
 Pharmaceuticals' filings with the Securities and Exchange Commission.
 
 SOURCE  OSI Pharmaceuticals, Inc.

RELATED LINKS

http://www.oncogene.com